For decades, Mauritius has figured among the top 10 countries with the highest incidence of type 2 diabetes (T2D). 29% of all deaths is directly linked to T2D, ranking the island as number two worldwide for diabetes-associated deaths. Among children aged 5-18 years, 22% are overweight, with elevated blood glucose levels. Due to its unique multi-ethnic population (of Indian, African, Chinese and Caucasian background) and compelling disease profile, Mauritius represents a fresh model for clinical research in T2D and related co-morbidities.

The presentation describes the local diseases and abundance of drug-naïve patients, the legal regulatory framework for conducting clinical studies, and the competence and infrastructure of the island for participating in multi-centric studies. We will also discuss the support that CIDP can offer as a CRO in facilitating clinical trials in Mauritius.

Latest News
  • 29 May 2020 COVID-19 Response
  • 20 May 2020 Happy International Clinical Trials Day!
  • 17 April 2020 CIDP accelerates its digitalization programme to cope with COVID-19 challenges
Archives

Time Zone

Choose a centre